The Experts below are selected from a list of 15996 Experts worldwide ranked by ideXlab platform
Danilo Fliser - One of the best experts on this subject based on the ideXlab platform.
-
treatment of severe refractory pruritus with fractionated plasma separation and adsorption Prometheus
Scandinavian Journal of Gastroenterology, 2006Co-Authors: K Rifai, Michael P. Manns, Hermann Haller, Carsten Hafer, Jens Rosenau, Christoph Athmann, Danilo FliserAbstract:Objective. Severe pruritus is a serious complication of cholestatic liver disease. Prometheus® is a recently introduced extracorporeal liver support system with direct toxin adsorption of the patient's albumin fraction (FPSA; fractionated plasma separation and adsorption). Here we report on the effect of Prometheus therapy in patients with intractable cholestatic pruritus. Material and methods. Seven patients with different liver diseases and severe pruritus refractory to all medical treatment efforts for more than 4 weeks were treated with Prometheus (3–5 times, 18±3 h total). Pruritus intensity was assessed using the visual analogue scale (VAS; from 0 = no pruritus to 10 = unbearable pruritus), and VAS, serum bile acids and total bilirubin were evaluated directly before and after Prometheus treatment, as well as 4 weeks later. Results. After Prometheus therapy, VAS values had dropped significantly from 9±1 to 3±3 (p<0.001). Likewise, serum bile acids decreased (from 248±192 to 101±85 µmol/l; p<0.03). Al...
-
removal selectivity of Prometheus a new extracorporeal liver support device
World Journal of Gastroenterology, 2006Co-Authors: K Rifai, Michael P. Manns, Thomas Ernst, Ulrich Kretschmer, Hermann Haller, Danilo FliserAbstract:AIM: To evaluate whether treatment with the Prometheus® system significantly affects cytokines, coagulation factors and other plasma proteins. METHODS: We studied nine patients with acute-on-chronic liver failure and accompanying renal failure. Prometheus® therapy was performed on 2 consecutive days for up to 6 h in all patients. Several biochemical parameters and blood counts were assessed at regular time points during Prometheus® treatment. RESULTS: We observed a significant decrease of both protein-bound (e.g. bile acids) and water-soluble (e.g. ammonia) substances after Prometheus® therapy. Even though leukocytes increased during treatment (P 0.5). Further, antithrombin 3, factor II and factor V plasma levels did not decrease during Prometheus® therapy (all P > 0.5), and the INR remained unchanged (P = 0.4). Plasma levels of total protein, albumin, and fibrinogen were also not altered during Prometheus® treatment (all P > 0.5). Finally, platelet count did not change significantly during therapy (P = 0.6). CONCLUSION: Despite significant removal of protein-bound and water-soluble substances, Prometheus® therapy did not affect the level of cytokines, coagulation factors or other plasma proteins. Thus, the filters and adsorbers used in the system are highly effective and specific for water-soluble substances and toxins bound to the albumin fraction.
-
Removal selectivity of Prometheus: A new extracorporeal liver support device
World Journal of Gastroenterology, 2006Co-Authors: Kinan Rifai, Michael P. Manns, Thomas Ernst, Ulrich Kretschmer, Hermann Haller, Danilo FliserAbstract:AIM: To evaluate whether treatment with the Prometheus® system significantly affects cytokines, coagulation factors and other plasma proteins. METHODS: We studied nine patients with acute-on-chronic liver failure and accompanying renal failure. Prometheus® therapy was performed on 2 consecutive days for up to 6 h in all patients. Several biochemical parameters and blood counts were assessed at regular time points during Prometheus® treatment. RESULTS: We observed a significant decrease of both protein-bound (e.g. bile acids) and water-soluble (e.g. ammonia) substances after Prometheus® therapy. Even though leukocytes increased during treatment (P 0.5). Further, antithrombin 3, factor II and factor V plasma levels did not decrease during Prometheus® therapy (all P > 0.5), and the INR remained unchanged (P = 0.4). Plasma levels of total protein, albumin, and fibrinogen were also not altered during Prometheus® treatment (all P > 0.5). Finally, platelet count did not change significantly during therapy (P = 0.6). CONCLUSION: Despite significant removal of protein-bound and water-soluble substances, Prometheus® therapy did not affect the level of cytokines, coagulation factors or other plasma proteins. Thus, the filters and adsorbers used in the system are highly effective and specific for water-soluble substances and toxins bound to the albumin fraction.
-
Treatment of severe refractory pruritus with fractionated plasma separation and adsorption (Prometheus).
Scandinavian Journal of Gastroenterology, 2006Co-Authors: Kinan Rifai, Michael P. Manns, Hermann Haller, Carsten Hafer, Jens Rosenau, Christoph Athmann, Danilo FliserAbstract:Objective. Severe pruritus is a serious complication of cholestatic liver disease. Prometheus® is a recently introduced extracorporeal liver support system with direct toxin adsorption of the patient's albumin fraction (FPSA; fractionated plasma separation and adsorption). Here we report on the effect of Prometheus therapy in patients with intractable cholestatic pruritus. Material and methods. Seven patients with different liver diseases and severe pruritus refractory to all medical treatment efforts for more than 4 weeks were treated with Prometheus (3–5 times, 18±3 h total). Pruritus intensity was assessed using the visual analogue scale (VAS; from 0 = no pruritus to 10 = unbearable pruritus), and VAS, serum bile acids and total bilirubin were evaluated directly before and after Prometheus treatment, as well as 4 weeks later. Results. After Prometheus therapy, VAS values had dropped significantly from 9±1 to 3±3 (p
-
Prometheus--a new extracorporeal system for the treatment of liver failure.
Journal of Hepatology, 2003Co-Authors: Kinan Rifai, Michael P. Manns, Thomas Ernst, Ulrich Kretschmer, Hermann Haller, Matthias J. Bahr, Andrea L.c. Schneider, Carsten Hafer, Danilo FliserAbstract:Abstract Background/Aims : Extracorporeal detoxification systems for supportive therapy of liver failure have recently gained much interest. We herein report results from the first clinical application of Prometheus ® , a new liver support system in which albumin-bound substances are directly removed from blood by special adsorber. In a simultaneous step, high-flux hemodialysis is performed. We assessed safety, adsorber efficiency and clinical efficacy of the Prometheus ® system. Methods : Eleven patients with acute-on-chronic liver failure and accompanying renal failure were treated with Prometheus ® on 2 consecutive days for >4 h. Results : Prometheus ® treatment significantly improved serum levels of conjugated bilirubin, bile acids, ammonia, cholinesterase, creatinine, urea and blood pH. There were no significant changes in hemoglobin and platelet levels, whereas leucocytes increased without signs of systemic infection. No treatment-related complications except a blood pressure drop in two patients with systemic infection were noted. In one patient (Child-Pugh score: 15) Prometheus ® treatment could not be completed due to onset of uncontrolled bleeding 16 h after dialysis. Conclusions : Prometheus ® is a safe supportive therapy for patients with liver failure. A significant improvement of the biochemical milieu was observed already after two treatments. Prospective controlled studies with the Prometheus ® system are necessary to evaluate hard clinical end-points.
Michael P. Manns - One of the best experts on this subject based on the ideXlab platform.
-
treatment of severe refractory pruritus with fractionated plasma separation and adsorption Prometheus
Scandinavian Journal of Gastroenterology, 2006Co-Authors: K Rifai, Michael P. Manns, Hermann Haller, Carsten Hafer, Jens Rosenau, Christoph Athmann, Danilo FliserAbstract:Objective. Severe pruritus is a serious complication of cholestatic liver disease. Prometheus® is a recently introduced extracorporeal liver support system with direct toxin adsorption of the patient's albumin fraction (FPSA; fractionated plasma separation and adsorption). Here we report on the effect of Prometheus therapy in patients with intractable cholestatic pruritus. Material and methods. Seven patients with different liver diseases and severe pruritus refractory to all medical treatment efforts for more than 4 weeks were treated with Prometheus (3–5 times, 18±3 h total). Pruritus intensity was assessed using the visual analogue scale (VAS; from 0 = no pruritus to 10 = unbearable pruritus), and VAS, serum bile acids and total bilirubin were evaluated directly before and after Prometheus treatment, as well as 4 weeks later. Results. After Prometheus therapy, VAS values had dropped significantly from 9±1 to 3±3 (p<0.001). Likewise, serum bile acids decreased (from 248±192 to 101±85 µmol/l; p<0.03). Al...
-
removal selectivity of Prometheus a new extracorporeal liver support device
World Journal of Gastroenterology, 2006Co-Authors: K Rifai, Michael P. Manns, Thomas Ernst, Ulrich Kretschmer, Hermann Haller, Danilo FliserAbstract:AIM: To evaluate whether treatment with the Prometheus® system significantly affects cytokines, coagulation factors and other plasma proteins. METHODS: We studied nine patients with acute-on-chronic liver failure and accompanying renal failure. Prometheus® therapy was performed on 2 consecutive days for up to 6 h in all patients. Several biochemical parameters and blood counts were assessed at regular time points during Prometheus® treatment. RESULTS: We observed a significant decrease of both protein-bound (e.g. bile acids) and water-soluble (e.g. ammonia) substances after Prometheus® therapy. Even though leukocytes increased during treatment (P 0.5). Further, antithrombin 3, factor II and factor V plasma levels did not decrease during Prometheus® therapy (all P > 0.5), and the INR remained unchanged (P = 0.4). Plasma levels of total protein, albumin, and fibrinogen were also not altered during Prometheus® treatment (all P > 0.5). Finally, platelet count did not change significantly during therapy (P = 0.6). CONCLUSION: Despite significant removal of protein-bound and water-soluble substances, Prometheus® therapy did not affect the level of cytokines, coagulation factors or other plasma proteins. Thus, the filters and adsorbers used in the system are highly effective and specific for water-soluble substances and toxins bound to the albumin fraction.
-
Review article: clinical experience with Prometheus.
Therapeutic Apheresis and Dialysis, 2006Co-Authors: Kinan Rifai, Michael P. MannsAbstract:: Prometheus is a new extracorporeal liver support device which facilitates the combined removal of both albumin-bound and water-soluble toxins based upon the method of fractionated plasma separation and adsorption (FPSA). The pilot trial included 11 patients with acute-on-chronic liver failure and concomitant renal failure. Prometheus therapy was found to be safe except for a reversible decrease of blood pressure. In three patients, clotting of the secondary system occurred. Prometheus treatment significantly improved blood levels of protein-bound (conjugated bilirubin, bile acids, ammonia) and water-soluble (creatinine, urea) substances. Thus, Prometheus might be a new therapeutic option in patients with severe hepatorenal syndrome. Furthermore, there is some preliminary experience with Prometheus in the treatment of refractory cholestatic pruritus and in successful bridging to liver transplantation. In order to compare extraction capacities of Prometheus and the molecular adsorbent recirculating system (MARS), five patients were crossover-treated with both systems. Prometheus resulted in significantly higher reduction ratios of bilirubin, ammonia and urea. Another study closely monitored whether the device causes an unselective removal. Neither important cytokines nor coagulation factors were found to be removed. In conclusion, Prometheus seems to be a new therapeutic option in artificial liver support. A significant improvement of the biochemical milieu was already observed after two treatments. The potential to remove protein-bound and water-soluble substances has been shown without signs of a significant unselective removal.
-
Removal selectivity of Prometheus: A new extracorporeal liver support device
World Journal of Gastroenterology, 2006Co-Authors: Kinan Rifai, Michael P. Manns, Thomas Ernst, Ulrich Kretschmer, Hermann Haller, Danilo FliserAbstract:AIM: To evaluate whether treatment with the Prometheus® system significantly affects cytokines, coagulation factors and other plasma proteins. METHODS: We studied nine patients with acute-on-chronic liver failure and accompanying renal failure. Prometheus® therapy was performed on 2 consecutive days for up to 6 h in all patients. Several biochemical parameters and blood counts were assessed at regular time points during Prometheus® treatment. RESULTS: We observed a significant decrease of both protein-bound (e.g. bile acids) and water-soluble (e.g. ammonia) substances after Prometheus® therapy. Even though leukocytes increased during treatment (P 0.5). Further, antithrombin 3, factor II and factor V plasma levels did not decrease during Prometheus® therapy (all P > 0.5), and the INR remained unchanged (P = 0.4). Plasma levels of total protein, albumin, and fibrinogen were also not altered during Prometheus® treatment (all P > 0.5). Finally, platelet count did not change significantly during therapy (P = 0.6). CONCLUSION: Despite significant removal of protein-bound and water-soluble substances, Prometheus® therapy did not affect the level of cytokines, coagulation factors or other plasma proteins. Thus, the filters and adsorbers used in the system are highly effective and specific for water-soluble substances and toxins bound to the albumin fraction.
-
Treatment of severe refractory pruritus with fractionated plasma separation and adsorption (Prometheus).
Scandinavian Journal of Gastroenterology, 2006Co-Authors: Kinan Rifai, Michael P. Manns, Hermann Haller, Carsten Hafer, Jens Rosenau, Christoph Athmann, Danilo FliserAbstract:Objective. Severe pruritus is a serious complication of cholestatic liver disease. Prometheus® is a recently introduced extracorporeal liver support system with direct toxin adsorption of the patient's albumin fraction (FPSA; fractionated plasma separation and adsorption). Here we report on the effect of Prometheus therapy in patients with intractable cholestatic pruritus. Material and methods. Seven patients with different liver diseases and severe pruritus refractory to all medical treatment efforts for more than 4 weeks were treated with Prometheus (3–5 times, 18±3 h total). Pruritus intensity was assessed using the visual analogue scale (VAS; from 0 = no pruritus to 10 = unbearable pruritus), and VAS, serum bile acids and total bilirubin were evaluated directly before and after Prometheus treatment, as well as 4 weeks later. Results. After Prometheus therapy, VAS values had dropped significantly from 9±1 to 3±3 (p
Hermann Haller - One of the best experts on this subject based on the ideXlab platform.
-
treatment of severe refractory pruritus with fractionated plasma separation and adsorption Prometheus
Scandinavian Journal of Gastroenterology, 2006Co-Authors: K Rifai, Michael P. Manns, Hermann Haller, Carsten Hafer, Jens Rosenau, Christoph Athmann, Danilo FliserAbstract:Objective. Severe pruritus is a serious complication of cholestatic liver disease. Prometheus® is a recently introduced extracorporeal liver support system with direct toxin adsorption of the patient's albumin fraction (FPSA; fractionated plasma separation and adsorption). Here we report on the effect of Prometheus therapy in patients with intractable cholestatic pruritus. Material and methods. Seven patients with different liver diseases and severe pruritus refractory to all medical treatment efforts for more than 4 weeks were treated with Prometheus (3–5 times, 18±3 h total). Pruritus intensity was assessed using the visual analogue scale (VAS; from 0 = no pruritus to 10 = unbearable pruritus), and VAS, serum bile acids and total bilirubin were evaluated directly before and after Prometheus treatment, as well as 4 weeks later. Results. After Prometheus therapy, VAS values had dropped significantly from 9±1 to 3±3 (p<0.001). Likewise, serum bile acids decreased (from 248±192 to 101±85 µmol/l; p<0.03). Al...
-
removal selectivity of Prometheus a new extracorporeal liver support device
World Journal of Gastroenterology, 2006Co-Authors: K Rifai, Michael P. Manns, Thomas Ernst, Ulrich Kretschmer, Hermann Haller, Danilo FliserAbstract:AIM: To evaluate whether treatment with the Prometheus® system significantly affects cytokines, coagulation factors and other plasma proteins. METHODS: We studied nine patients with acute-on-chronic liver failure and accompanying renal failure. Prometheus® therapy was performed on 2 consecutive days for up to 6 h in all patients. Several biochemical parameters and blood counts were assessed at regular time points during Prometheus® treatment. RESULTS: We observed a significant decrease of both protein-bound (e.g. bile acids) and water-soluble (e.g. ammonia) substances after Prometheus® therapy. Even though leukocytes increased during treatment (P 0.5). Further, antithrombin 3, factor II and factor V plasma levels did not decrease during Prometheus® therapy (all P > 0.5), and the INR remained unchanged (P = 0.4). Plasma levels of total protein, albumin, and fibrinogen were also not altered during Prometheus® treatment (all P > 0.5). Finally, platelet count did not change significantly during therapy (P = 0.6). CONCLUSION: Despite significant removal of protein-bound and water-soluble substances, Prometheus® therapy did not affect the level of cytokines, coagulation factors or other plasma proteins. Thus, the filters and adsorbers used in the system are highly effective and specific for water-soluble substances and toxins bound to the albumin fraction.
-
Removal selectivity of Prometheus: A new extracorporeal liver support device
World Journal of Gastroenterology, 2006Co-Authors: Kinan Rifai, Michael P. Manns, Thomas Ernst, Ulrich Kretschmer, Hermann Haller, Danilo FliserAbstract:AIM: To evaluate whether treatment with the Prometheus® system significantly affects cytokines, coagulation factors and other plasma proteins. METHODS: We studied nine patients with acute-on-chronic liver failure and accompanying renal failure. Prometheus® therapy was performed on 2 consecutive days for up to 6 h in all patients. Several biochemical parameters and blood counts were assessed at regular time points during Prometheus® treatment. RESULTS: We observed a significant decrease of both protein-bound (e.g. bile acids) and water-soluble (e.g. ammonia) substances after Prometheus® therapy. Even though leukocytes increased during treatment (P 0.5). Further, antithrombin 3, factor II and factor V plasma levels did not decrease during Prometheus® therapy (all P > 0.5), and the INR remained unchanged (P = 0.4). Plasma levels of total protein, albumin, and fibrinogen were also not altered during Prometheus® treatment (all P > 0.5). Finally, platelet count did not change significantly during therapy (P = 0.6). CONCLUSION: Despite significant removal of protein-bound and water-soluble substances, Prometheus® therapy did not affect the level of cytokines, coagulation factors or other plasma proteins. Thus, the filters and adsorbers used in the system are highly effective and specific for water-soluble substances and toxins bound to the albumin fraction.
-
Treatment of severe refractory pruritus with fractionated plasma separation and adsorption (Prometheus).
Scandinavian Journal of Gastroenterology, 2006Co-Authors: Kinan Rifai, Michael P. Manns, Hermann Haller, Carsten Hafer, Jens Rosenau, Christoph Athmann, Danilo FliserAbstract:Objective. Severe pruritus is a serious complication of cholestatic liver disease. Prometheus® is a recently introduced extracorporeal liver support system with direct toxin adsorption of the patient's albumin fraction (FPSA; fractionated plasma separation and adsorption). Here we report on the effect of Prometheus therapy in patients with intractable cholestatic pruritus. Material and methods. Seven patients with different liver diseases and severe pruritus refractory to all medical treatment efforts for more than 4 weeks were treated with Prometheus (3–5 times, 18±3 h total). Pruritus intensity was assessed using the visual analogue scale (VAS; from 0 = no pruritus to 10 = unbearable pruritus), and VAS, serum bile acids and total bilirubin were evaluated directly before and after Prometheus treatment, as well as 4 weeks later. Results. After Prometheus therapy, VAS values had dropped significantly from 9±1 to 3±3 (p
-
Prometheus--a new extracorporeal system for the treatment of liver failure.
Journal of Hepatology, 2003Co-Authors: Kinan Rifai, Michael P. Manns, Thomas Ernst, Ulrich Kretschmer, Hermann Haller, Matthias J. Bahr, Andrea L.c. Schneider, Carsten Hafer, Danilo FliserAbstract:Abstract Background/Aims : Extracorporeal detoxification systems for supportive therapy of liver failure have recently gained much interest. We herein report results from the first clinical application of Prometheus ® , a new liver support system in which albumin-bound substances are directly removed from blood by special adsorber. In a simultaneous step, high-flux hemodialysis is performed. We assessed safety, adsorber efficiency and clinical efficacy of the Prometheus ® system. Methods : Eleven patients with acute-on-chronic liver failure and accompanying renal failure were treated with Prometheus ® on 2 consecutive days for >4 h. Results : Prometheus ® treatment significantly improved serum levels of conjugated bilirubin, bile acids, ammonia, cholinesterase, creatinine, urea and blood pH. There were no significant changes in hemoglobin and platelet levels, whereas leucocytes increased without signs of systemic infection. No treatment-related complications except a blood pressure drop in two patients with systemic infection were noted. In one patient (Child-Pugh score: 15) Prometheus ® treatment could not be completed due to onset of uncontrolled bleeding 16 h after dialysis. Conclusions : Prometheus ® is a safe supportive therapy for patients with liver failure. A significant improvement of the biochemical milieu was observed already after two treatments. Prospective controlled studies with the Prometheus ® system are necessary to evaluate hard clinical end-points.
K Rifai - One of the best experts on this subject based on the ideXlab platform.
-
treatment of severe refractory pruritus with fractionated plasma separation and adsorption Prometheus
Scandinavian Journal of Gastroenterology, 2006Co-Authors: K Rifai, Michael P. Manns, Hermann Haller, Carsten Hafer, Jens Rosenau, Christoph Athmann, Danilo FliserAbstract:Objective. Severe pruritus is a serious complication of cholestatic liver disease. Prometheus® is a recently introduced extracorporeal liver support system with direct toxin adsorption of the patient's albumin fraction (FPSA; fractionated plasma separation and adsorption). Here we report on the effect of Prometheus therapy in patients with intractable cholestatic pruritus. Material and methods. Seven patients with different liver diseases and severe pruritus refractory to all medical treatment efforts for more than 4 weeks were treated with Prometheus (3–5 times, 18±3 h total). Pruritus intensity was assessed using the visual analogue scale (VAS; from 0 = no pruritus to 10 = unbearable pruritus), and VAS, serum bile acids and total bilirubin were evaluated directly before and after Prometheus treatment, as well as 4 weeks later. Results. After Prometheus therapy, VAS values had dropped significantly from 9±1 to 3±3 (p<0.001). Likewise, serum bile acids decreased (from 248±192 to 101±85 µmol/l; p<0.03). Al...
-
removal selectivity of Prometheus a new extracorporeal liver support device
World Journal of Gastroenterology, 2006Co-Authors: K Rifai, Michael P. Manns, Thomas Ernst, Ulrich Kretschmer, Hermann Haller, Danilo FliserAbstract:AIM: To evaluate whether treatment with the Prometheus® system significantly affects cytokines, coagulation factors and other plasma proteins. METHODS: We studied nine patients with acute-on-chronic liver failure and accompanying renal failure. Prometheus® therapy was performed on 2 consecutive days for up to 6 h in all patients. Several biochemical parameters and blood counts were assessed at regular time points during Prometheus® treatment. RESULTS: We observed a significant decrease of both protein-bound (e.g. bile acids) and water-soluble (e.g. ammonia) substances after Prometheus® therapy. Even though leukocytes increased during treatment (P 0.5). Further, antithrombin 3, factor II and factor V plasma levels did not decrease during Prometheus® therapy (all P > 0.5), and the INR remained unchanged (P = 0.4). Plasma levels of total protein, albumin, and fibrinogen were also not altered during Prometheus® treatment (all P > 0.5). Finally, platelet count did not change significantly during therapy (P = 0.6). CONCLUSION: Despite significant removal of protein-bound and water-soluble substances, Prometheus® therapy did not affect the level of cytokines, coagulation factors or other plasma proteins. Thus, the filters and adsorbers used in the system are highly effective and specific for water-soluble substances and toxins bound to the albumin fraction.
Michael Winikoff - One of the best experts on this subject based on the ideXlab platform.
-
Requirements specification via activity diagrams for agent-based systems
Autonomous Agents and Multi-Agent Systems, 2017Co-Authors: Yoosef Abushark, Michael Winikoff, John Thangarajah, Tim Miller, James HarlandAbstract:Goal-oriented agent systems are increasingly popular for developing complex applications that operate in highly dynamic environments. As with any software these systems have to be designed starting with the specification of system requirements. In this paper, we extend a popular agent design methodology, Prometheus, and improve the understandability and maintainability of requirements by automatically generating UML activity diagrams from existing requirements models; namely scenarios and goal hierarchies. This approach aims to overcome some of the ambiguity present in the current requirements specification in Prometheus and provide more structure for representing variations. Even though our approach is grounded in Prometheus, it can be generalised to all the methodologies that support similar notions in specifying requirements (i.e. notions of goals and scenarios). We present our approach and an evaluation based on user experiments. The evaluation showed that the activity diagram based approach enhances people’s understanding of the requirements, makes it easier to modify requirements, and easier to check them against the detailed design of the agents for coverage.
-
AAAI - Prometheus design tool
2008Co-Authors: Lin Padgham, John Thangarajah, Michael WinikoffAbstract:The Prometheus Design Tool (PDT) supports the structured design of intelligent agent systems. It supports the Prometheus methodology, but can also be used more generally. This paper outlines the tool and some of its many features.
-
Prometheus design tool
National Conference on Artificial Intelligence, 2008Co-Authors: Lin Padgham, John Thangarajah, Michael WinikoffAbstract:The Prometheus Design Tool (PDT) supports the structured design of intelligent agent systems. It supports the Prometheus methodology, but can also be used more generally. This paper outlines the tool and some of its many features.
-
AAMAS - AUML protocols and code generation in the Prometheus design tool
Proceedings of the 6th international joint conference on Autonomous agents and multiagent systems - AAMAS '07, 2007Co-Authors: Lin Padgham, John Thangarajah, Michael WinikoffAbstract:Prometheus is an agent-oriented software engineering methodology. The Prometheus Design Tool (PDT) is a software tool that supports a designer who is using the Prometheus methodology. PDT has recently been extended with two significant new features: support for Agent UML interaction protocols, and code generation.
-
tool support for agent development using the Prometheus methodology
International Conference on Quality Software, 2005Co-Authors: Lin Padgham, John Thangarajah, Michael WinikoffAbstract:We believe that tool support is very important for any methodology. In this paper we describe PDT (Prometheus design tool) which supports the design of an intelligent agent system using the Prometheus methodology. We describe how PDT supports the various stages of Prometheus through various means such as consistency checking, support for entity propagation, and hierarchical views. We also describe works that are currently in progress which involves the development of a plug-in for Eclipse with the aim of creating a single integrated development environment which would support the complete development cycle of an agent system from design to deployment.
